Pediatric Puzzler: He won't walk and isn't talking much—what's the next step for a 2-year-old?

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.